Shorter Radiotherapy Schedule Tested for Localized Prostate Cancer
Tests higher doses of radiation given over fewer visits in adults with localized prostate cancer.
Plain-language title generated from the registry record
Registry title: Radical Hypofractionated Radiotherapy for Localized Prostate Cancer
Key facts
- Where
- Shanghai, ChinaSee the site
Where in China
- Changhai HospitalShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Changhai Hospital
- Trial code
- NCT06325774
- Record updated
- 26 August 2024
- Original description
The aim of this trial is to study the safety outcomes of hypofractionated radiotherapy in treating patients with localized prostate cancer.Read full original descriptionShow less
Safety and Efficacy Study of Hypofractionated Radiotherapy for Localized Prostate Cancer: a Single-arm Clinical Trial
The aim of this trial is to study the safety outcomes of hypofractionated radiotherapy in treating patients with localized prostate cancer.
Hypofractionated radiotherapy delivers higher doses of radiotherapy in a shorter time period, may enabling the killing of more tumor cells with fewer side effects.
Accumulating evidence has proven the safety and feasibility of hypofractionated radiotherapy for localized prostate cancer.But for localized prostate cancer,the optimal dose per fraction of hypofractionated radiotherapy is still on its way.
Inclusion: Age: ≥18 years old; European Cooperative Oncology Group score(ECOG):≤ 2; Patients with pathologically diagnosed prostate cancer; Clinical stage was cTanyN0M0 any Gleason / ISUP group; Expected survival time >5 years; The patient has no contraindications to radiotherapy and is suitable and willing to undergo radiotherapy; Patients who voluntarily accept the experimental study protocol after being informed about the existing treatment options.
Exclusion: Patients who have received any other early treatment for prostate cancer, including radiotherapy, chemotherapy, focal therapy, etc; a previous history of pelvic and abdominal radiotherapy; Prior hormonal therapy (castration or antiandrogen); Patients with contraindications related to radiotherapy; Participate in other clinical trials that are mutually exclusive with the study intervention within 4 weeks prior to the start of the study; Patients with other malignancies and acute or chronic infections such as human immunodeficiency virus (HIV) (+), hepatitis C virus (HCV) (+) and/or positive syphilis; Patients that the investigator considers unsuitable to participate in the clinical trial; patients with other serious systemic diseases, evaluation and compliance of the trial, including severe respiratory, circulatory, neurological, mental, digestive, endocrine, immune, urinary, and other systemic diseases; Patients unable to provide written informed consent or demonstrate poor treatment compliance.